Compare Nokia Corp (NOK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Summit Therapeutics Inc — how do they compare? Nokia Corp trades at $10.81 (market cap $59.77B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Nokia Corp is far larger — about 4.3× Summit Therapeutics Inc's market cap, and Nokia Corp pays a 1.53% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NOK | SMMT | |
|---|---|---|
Market Cap | $59.77B | $13.79B |
Sector | Technology | Health |
52-Week High | $16.83 | $26.38 |
52-Week Low | $4.51 | $12.43 |
Enterprise Value | $57.71B | $13.11B |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue trends stabilize around $20B annually. The company maintains a solid balance sheet with $8.91B cash and reduced debt-to-asset ratio of 9.09 in 2025. Positive news includes AI-driven network expansion and Euro Stoxx 50 reinstatement, though cash flow volatility and competitive pressures persist.
Outlook: Growth is supported by AI infrastructure demand and portfolio diversification, but risks include execution challenges and margin pressures. With 61.5% analyst buy ratings and technical momentum, the stock offers upside potential, though investors should weigh high P/E of 76.42 against earnings consistency and free cash flow trends.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
